<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318224</url>
  </required_header>
  <id_info>
    <org_study_id>FiX</org_study_id>
    <nct_id>NCT03318224</nct_id>
  </id_info>
  <brief_title>Fatigue Prevalence, Severity, and State of Treatment in Germany</brief_title>
  <acronym>FiX</acronym>
  <official_title>Fatigue in Germany - Examination of Prevalence, Severity, and State of Screening and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatigue is a major concern during and after cancer therapy with severe impact on quality of&#xD;
      life. Yet, sound comparable data on fatigue prevalence, severity, and impact on daily life&#xD;
      across different tumor entities is lacking. Furthermore, little is known about the current&#xD;
      state of screening, counselling and treatment of fatigue.&#xD;
&#xD;
      Thus, the FiX-Study aims to assess such data to identify patient groups with especial need&#xD;
      for an improved fatigue management and treatment.&#xD;
&#xD;
      A minimum of n=3000 patients about equally distributed about the 16 most common tumor&#xD;
      entities shall be recruited between year 1 and 2 after primary cancer diagnosis via the&#xD;
      cancer registry Baden-Württemberg. Data on fatigue (EORTC QLQ-FA12, BFI), quality of life&#xD;
      (EORTC QLQ-C30), depression and anxiety (PAQ-4), and information about screening and&#xD;
      treatment of fatigue will be assessed via self-reported questionnaires. Clinical data&#xD;
      regarding tumor and treatment characteristics will be derived from the cancer registry.&#xD;
&#xD;
      This trial is imbedded in a larger research agenda on fatigue and will provide the basis for&#xD;
      the development of an individually-tailored fatigue program.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Actual">May 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EORTC QLQ-FA12</measure>
    <time_frame>Assessment time point: about 1-2 years post-diagnosis</time_frame>
    <description>12-item multidimensional fatigue questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Fatigue Inventory (BFI)</measure>
    <time_frame>Assessment time point: about 1-2 years post-diagnosis</time_frame>
    <description>Questionnaire on the impact of fatigue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30</measure>
    <time_frame>Assessment time point: about 1-2 years post-diagnosis</time_frame>
    <description>Quality of Life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHQ-4</measure>
    <time_frame>Assessment time point: about 1-2 years post-diagnosis</time_frame>
    <description>Anxiety and Depression Screen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State of fatigue management</measure>
    <time_frame>Assessment time point: about 1-2 years post-diagnosis</time_frame>
    <description>Questionnaire on Screening, primary evaluation, and received counseling, treatment and interventions for fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's believes and knowledge with regard to fatigue</measure>
    <time_frame>Assessment time point: about 1-2 years post-diagnosis</time_frame>
    <description>7 Likert-items regarding believes and knowledge about fatigue</description>
  </secondary_outcome>
  <enrollment type="Actual">2508</enrollment>
  <condition>Cancer-related Fatigue</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>none (observational study)</intervention_name>
    <description>only assessments via questionnaires, no interventions</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients who were diagnosed 1-2 years ago&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of Age&#xD;
&#xD;
          -  Diagnosed with a primary tumor of one of the following malignant neoplasms (including&#xD;
             in-situ carcinoma): stomach (C16, D00.2), colon (C18, D01.0), rectum (C19-20,&#xD;
             D01.1-1.2), liver (C22, D01.5), pancreas (C25, D01.7), lung (C33-34, D02.1-2.2),&#xD;
             malignant melanoma (C43, D03), breast (C50, D05, female only), cervix or ovaries (C53,&#xD;
             D06), endometrium (C54.1, D07.0), ovaries (C56), prostate (C61), kidney (C64), bladder&#xD;
             (C67, D09.0), non-Hodgkin lymphoma (C82-88), leukemia (C91-C95)&#xD;
&#xD;
          -  Time since first diagnosis is at least 1 year, maximal 2 years&#xD;
&#xD;
          -  Able to understand and follow the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Any additional malignant or unclear neoplasm or carcinoma in situ at or since time of&#xD;
        diagnosis of the considered primary tumor, except non-malignant, unspecified, or in-situ&#xD;
        neoplasm of skin (C44 or D0.4)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>German Cancer Research Center</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Schmidt ME, Hermann S, Arndt V, Steindorf K. Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities. Cancer Med. 2020 Nov;9(21):8053-8061. doi: 10.1002/cam4.3413. Epub 2020 Sep 7.</citation>
    <PMID>32893501</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt ME, Bergbold S, Hermann S, Steindorf K. Knowledge, perceptions, and management of cancer-related fatigue: the patients' perspective. Support Care Cancer. 2021 Apr;29(4):2063-2071. doi: 10.1007/s00520-020-05686-5. Epub 2020 Aug 29.</citation>
    <PMID>32860177</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

